Top

Published in:

01-03-2013 | Thoracic Oncology

Esophageal Carcinosarcoma: A Unique Entity with Better Prognosis

Authors: Liang Wang, MD, Yongbin Lin, MD, Hao Long, MD, Hui Liu, MD, Huilan Rao, MD, Youjian He, MD, Tiehua Rong, MD, Ying Liang, MD

Published in: Annals of Surgical Oncology | Issue 3/2013

Abstract

Background

Esophageal carcinosarcoma is a rare kind of malignancy, and how to identify the patients with poor prognosis is critical for improving treatment efficacy and survival outcome.

Methods

The clinical characteristics, pathologic features, treatments, and outcomes of esophageal carcinosarcoma were analyzed in 33 patients. Meanwhile, we hypothesized that elevated neutrophil to lymphocyte ratio (NLR) correlates with poor prognosis.

Results

Most patients had polypoid tumors, and the carcinomatous elements were squamous in all patients except one with adenosquamous carcinoma. Eight patients had elevated NLR (≥5). The median follow-up time was 39.1 (range, 0.5–178.2) months. The median overall survival time (OS) was 43.5 months, and the 1-, 3-, and 5-year OS rates were 74, 57, and 48 %, respectively. Tumor recurrence occurred in 15 patients, and the median relapse-free survival time (RFS) was 23.9 months, and the 2-year RFS rate was 50 %. For patients who received curative resection, OS and RFS were significantly associated with preoperative NLR. In the multivariate Cox regression model, higher NLR was an independent prognostic factor (P value was 0.001 for both OS and RFS).

Conclusions

Our study identified the baseline NLR to be an independently prognostic factor for curatively resected esophageal carcinosarcoma.

Madan AK, Long AE, Weldon CB, Jaffe BM. Esophageal carcinosarcoma. J Gastrointest Surg. 2001;5:414–7.PubMedCrossRef

Xu LT, Sun CF, Wu LH, et al. Clinical and pathological characteristics of carcinosarcoma of the esophagus: report of four cases. Ann Thorac Surg. 1984;37:197–203.PubMedCrossRef

Iyomasa S, Kato H, Tachimori Y, et al. Carcinosarcoma of the esophagus: a twenty-case study. Jpn J Clin Oncol. 1990;20:99–106.PubMed

DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008;27:11–8.PubMedCrossRef

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.PubMedCrossRef

Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149–63.PubMedCrossRef

Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34:55–60.PubMedCrossRef

Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17(7):1721–4.PubMedCrossRef

Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91:181–4.PubMedCrossRef

10.

Kishi Y, Kopetz S, Chun YS, et al. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009;16:614–22.PubMedCrossRef

11.

Taniyama K, Sasaki N, Mukai T, et al. Carcinosarcomas of the esophagus. Pathol Int. 1995;45:297–302.PubMedCrossRef

12.

Enrile F, DeJesus PO, Bakst AA, Baluyot R. Pseudosarcoma of the esophagus. Cancer. 1973;21:1197–1202.CrossRef

13.

Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325(16):1127–31.PubMedCrossRef

14.

Rokkas T, Pistiolas D, Sechopoulos P, et al. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol. 2007;5(12):1413–7, 1417.e1-2.

15.

Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008;1(5):329–38.CrossRef

16.

Blaser MJ. The changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 1999;179:1523–30.PubMedCrossRef

17.

Blaser MJ, Atherton J. Helicobacter pylori persistence: biology and disease. J Clin Invest 2004;113:321–33.PubMed

18.

Wang KJ, Wang RT. Meta-analysis on the epidemiology of Helicobacter pylori infection in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2003;24:443–6.PubMed

19.

Matysiak-Budnik T, Mégraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer. 2006;42(6):708–16.PubMedCrossRef

20.

Sharaiha RZ, Halazun KJ, Mirza F, et al. Elevated preoperative neutrophil: lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011;18:3362–9.PubMedCrossRef

21.

Wada Y, Nakashima O, Kutami R, et al. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998;27:407–14.PubMedCrossRef

22.

Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.PubMedCrossRef

23.

Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283–7.PubMedCrossRef

24.

Fondevila C, Metges JP, Fuster J, et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer. 2004;90:206–15.PubMedCrossRef

25.

Tanaka T, Ishiguro H, Kuwabara Y, et al. Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res. 2010;29:83.PubMedCrossRef

26.

van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-84.PubMedCrossRef

27.

Kuo CJ, Lin TN, Lin CJ, et al. Clinical manifestation of esophageal carcinosarcoma: a Taiwan experience. Dis Esophagus. 2010;23:122–7.PubMedCrossRef

28.

Zhang DK, Su XD, Long H, et al. Surgical treatment and prognosis in patients with squamous cell carcinoma of thoracic esophagus. Zhonghua Wai Ke Za Zhi. 2008;46(17):1333–6.PubMed

Title: Esophageal Carcinosarcoma: A Unique Entity with Better Prognosis
Authors: Liang Wang, MD
Yongbin Lin, MD
Hao Long, MD
Hui Liu, MD
Huilan Rao, MD
Youjian He, MD
Tiehua Rong, MD
Ying Liang, MD
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 3/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-012-2658-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Esophageal Carcinosarcoma: A Unique Entity with Better Prognosis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2013

Outcomes After Adjuvant Platinum-based Chemotherapy in Elderly NSCLC Patients with T4 Disease

Can Minimally Invasive Follicular Thyroid Cancer be Approached as a Benign Lesion?

Adenocarcinoma of the Esophagogastric Junction: Territory of the Esophagus or Stomach, or an Independent Region?

Development of Criteria for Ovarian Preservation in Cervical Cancer Patients Treated with Radical Surgery With or Without Neoadjuvant Chemotherapy: A Multicenter Retrospective Study and Meta-analysis

Management of Bowel Obstruction in Patients with Stage IV Cancer: Predictors of Outcome After Surgery

Elevated CEA Levels and Low Distance of the Tumor from the Anal Verge are Predictors of Incomplete Response to Chemoradiation in Patients with Rectal Cancer